Search
Dantrolene
go.drugbank.com/drugs/DB01219ApprovedInvestigationalChemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigational4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. … It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Dihydrocapsiate
go.drugbank.com/drugs/DB15398InvestigationalDihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).
Rogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Oleoyl-estrone
go.drugbank.com/drugs/DB04870InvestigationalThis hormone occurs naturally and is found circulating in various animal species and humans. … It has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance.
Pegargiminase
go.drugbank.com/drugs/DB06592InvestigationalPegargiminase is an anticancer agent.
Categories: Compounds used in a research, industrial, or household settingCOVID-19 convalescent plasma
go.drugbank.com/drugs/DB15692Investigational[L14333] This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305 … ), and use for single patients through an emergency IND (eIND; 21 CFR 312.310).
DNB-001
go.drugbank.com/drugs/DB05757InvestigationalIn preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve. … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.
Livoletide
go.drugbank.com/drugs/DB15188InvestigationalLivoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).